These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
97 related articles for article (PubMed ID: 8940308)
1. From the Centers for Disease Control and Prevention. Adverse events associated with ephedrine-containing products--Texas, December 1993-September 1995. JAMA; 1996 Dec; 276(21):1711-2. PubMed ID: 8940308 [No Abstract] [Full Text] [Related]
2. Adverse events associated with ephedrine-containing products--Texas, December 1993-September 1995. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 1996 Aug; 45(32):689-93. PubMed ID: 8772203 [TBL] [Abstract][Full Text] [Related]
3. Are serious adverse cardiovascular events an unintended consequence of the Dietary Supplement Health and Education Act of 1994? Lindsay BD Mayo Clin Proc; 2002 Jan; 77(1):7-9. PubMed ID: 11795250 [No Abstract] [Full Text] [Related]
8. Suicide attempt after use of herbal diet pill. Traboulsi AS; Viswanathan R; Coplan J Am J Psychiatry; 2002 Feb; 159(2):318-9. PubMed ID: 11823284 [No Abstract] [Full Text] [Related]
9. [Ephedrine and ephedra in weight loss products and other preparations]. van der Hooft CS; Stricker BH Ned Tijdschr Geneeskd; 2002 Jul; 146(28):1335-6. PubMed ID: 12148223 [TBL] [Abstract][Full Text] [Related]
10. Possible case of mania associated with ma-huang. Boerth JM; Caley CF Pharmacotherapy; 2003 Mar; 23(3):380-3. PubMed ID: 12627938 [TBL] [Abstract][Full Text] [Related]
12. ADHD drugs and cardiovascular risk. Nissen SE N Engl J Med; 2006 Apr; 354(14):1445-8. PubMed ID: 16549404 [No Abstract] [Full Text] [Related]
13. American Society for Clinical Pharmacology and Therapeutics position statement on the public health risks of ephedra. Hollister AS; Kearns GL Clin Pharmacol Ther; 2003 Nov; 74(5):403-5. PubMed ID: 14586380 [No Abstract] [Full Text] [Related]
14. [COLOR REACTIONS FOR THE IDENTIFICATION OF SOME DRUGS WITH CENTRAL STIMULATING AND-OR APPETITE CONTROLLING PROPERTIES ON THE PAPER CHROMATOGRAM]. FREUNDT KJ; SCHWINGER G Arch Toxikol; 1964 May; 20():257-62. PubMed ID: 14230788 [No Abstract] [Full Text] [Related]
15. FDA proposes constraints on ephedrine dietary supplements. Am J Health Syst Pharm; 1997 Jul; 54(14):1578. PubMed ID: 9248599 [No Abstract] [Full Text] [Related]
16. Cardiovascular disease risk factors and symptoms among regular psychostimulant users. Darke S; Torok M; Kaye S; Duflou J Drug Alcohol Rev; 2010 Jul; 29(4):371-7. PubMed ID: 20636652 [TBL] [Abstract][Full Text] [Related]
17. Use of a prescribed ephedrine/caffeine combination and the risk of serious cardiovascular events: a registry-based case-crossover study. Hallas J; Bjerrum L; Støvring H; Andersen M Am J Epidemiol; 2008 Oct; 168(8):966-73. PubMed ID: 18756018 [TBL] [Abstract][Full Text] [Related]
18. [Liberalized use of Letigen--how is the documentation?]. Astrup AV Ugeskr Laeger; 2002 Oct; 164(42):4942-3; author reply 4943-4. PubMed ID: 12416080 [No Abstract] [Full Text] [Related]
19. [Poisoning by anorexigenics. Information from the data bank of the Anti-Poison Center of Marseille (1973)]. Jouglard J; Brun A; Botta A Eur J Toxicol Environ Hyg; 1976; 9(3):197-90. PubMed ID: 954856 [TBL] [Abstract][Full Text] [Related]
20. [Obesity epidemic after Letigen]. von Eyben FE Ugeskr Laeger; 2002 Dec; 164(49):5820. PubMed ID: 12523231 [No Abstract] [Full Text] [Related] [Next] [New Search]